NexImmune

Gaithersburg, United States

NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.

$3.7M raised

Feb 2024

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has NexImmune raised?

NexImmune has raised $3.7M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2024.

Who are NexImmune's investors?

NexImmune's investors include New Enterprise Associates, Pfizer Venture Investments, ArrowMark Partners, Irving Investors, Amgen Ventures.

Where is NexImmune headquartered?

NexImmune is headquartered in Gaithersburg, United States.

What does NexImmune do?

NexImmune is a biopharmaceutical company developing novel immuno-therapeutics based on the proprietary artificial immune technology.

What stage is NexImmune at?

NexImmune is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 2, 2024.

MLA

"NexImmune — Funding & Investors." VCBacked, February 2, 2024, https://www.vcbacked.co/company/neximmune. Accessed July 2, 2026.

APA

VCBacked. (2024). NexImmune — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/neximmune

Wikipedia (cite web)

{{cite web |title=NexImmune — Funding & Investors |url=https://www.vcbacked.co/company/neximmune |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 2, 2024.